

REMARKS

Response to Restriction Requirement

The Examiner requires essentially that Applicants must elect two species for prosecution, namely, A) the wound healing therapeutic agent of claim 4 or claim 5 (i.e., Species 1 or Species 2 as defined by the Examiner), and B) the protease enzyme of claim 8, 9, 10, 11, 12 or 13 (i.e., Species 3 as defined by the Examiner). *See* paragraph 6 in the Office Action.

In reply to the Requirement for Election of Species, Applicants first elect Species 1, wherein the wound healing therapeutic agent and/or the inhibitor are conjugated to the medically acceptable polymer by the linker group. Claims 1-4 and 6-17 are readable on Species 1. Regarding Species 3, Applicants further elect the protease of claim 8, elastase. Claims 1-8 and 14-17 are readable on the elected species.

This election is made without prejudice to the inclusion of the non-elected subject matter in one or more divisional or continuation applications. The non-elected claims have been withdrawn from consideration at this time.

Claim Amendments

The claims have been amended herein to add sequence identifiers for the amino acid sequences, in compliance with 37 C.F.R. § 1.821 *et seq.*

Claim 15 has been amended to properly depend from claim 14, the preceding claim.

Claim 17 has been amended to depend from claim 1.

No new matter has been added by way of any of these amendments.

Amendments to the Specification

The specification has been amended herein, by way of a substitute specification, to add sequence identifiers for the amino acid sequences, in compliance with 37 C.F.R. § 1.821 *et seq.* Two copies of the substitute specification are enclosed herewith, a marked up copy and a clean copy.

No new matter has been added by way of the substitute specification.

Sequence Listing

A Sequence Listing is also being submitted in compliance with 37 C.F.R. § 1.821 *et seq.* A paper copy of the sequence is submitted herewith, as well as an electronic copy, which is filed herewith by way of the United States Patent and Trademark Office Electronic Business Center.

Applicants respectfully note that the reference by the Examiner to “claim 20”, on page 5 of the office action is assumed to be a typographic error, as there is no pending claim 20. All claims containing sequences requiring a sequence identifier have been amended in accordance with the requirements of 37 C.F.R. § 1.821 *et seq.* Accordingly, Applicants submit that the present application is in compliance with the Sequence Rules.

Summary

Favorable examination of the elected claims is respectfully requested. Applicants invite the Examiner to contact the undersigned at (215) 963-5809 to clarify any unresolved issues raised by this response.


The Director is hereby authorized to charge/credit Deposit Account No. **50-0310** (Billing No. 101713-5057) for any other required fees, deficiencies or overpayments in connection with this Response.

Respectfully submitted,

BREDA MARY CULLEN ET AL.

Date: March 15, 2010

By:


Thomas M. Sossong, Jr., Ph.D.
Registration No. **48,463**
MORGAN, LEWIS & BOCKIUS LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5809
Facsimile: (215) 963-5001
E-Mail: tsossong@morganlewis.com